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Abstract
The serotonin-1A (5-HT1A) receptor is among the most abundant and widely distributed 5-HT receptors in the
brain, but is also expressed on serotonin neurons as an autoreceptor where it plays a critical role in regulating the
activity of the entire serotonin system. Over-expression of the 5-HT1A autoreceptor has been implicated in
reducing serotonergic neurotransmission, and is associated with major depression and suicide. Extensive
characterization of the transcriptional regulation of the 5-HT1A gene (HTR1A) using cell culture systems has
revealed a GC-rich “housekeeping” promoter that non-selectively drives its expression; this is flanked by a series of
upstream repressor elements for REST, Freud-1/CC2D1A and Freud-2/CC2D1B factors that not only restrict its
expression to neurons, but may also regulate the level of expression of 5-HT1A receptors in various subsets of
neurons, including serotonergic neurons. A separate set of allele-specific factors, including Deaf1, Hes1 and Hes5
repress at the HTR1A C(-1019)G (rs6295) polymorphism in serotonergic neurons in culture, as well as in vivo. Pet1,
an obligatory enhancer for serotonergic differentiation, has been identified as a potent activator of 5-HT1A
autoreceptor expression. Taken together, these results highlight an integrated regulation of 5-HT1A autoreceptors
that differs in several aspects from regulation of post-synaptic 5-HT1A receptors, and could be selectively targeted
to enhance serotonergic neurotransmission.
Serotonin in Major Depression
Major depression is a common and severe mental illness
with a lifetime prevalence of 15% (1 in 6) compared
with 1% for schizophrenia, and is twice as frequent in
women as in men [1,2]. In developed countries, MDD
currently accounts for the second highest lifetime bur-
den of disease, and is forecast to be highest by 2030
[3-7]. With current antidepressant treatments, although
up to 60% of patients respond, only 30% go on to remis-
sion [8-13], and 15% attempt suicide [14,15]. Although
other neurotransmitters (e.g., noradrenaline, dopamine,
glutamate, neurotrophins) are indirectly involved in
depression [16-21], multiple lines of evidence implicate
reduced 5-HT neurotransmission as a primary defect in
depression [22-30]. For example, acute tryptophan
depletion triggers relapse in recovered depressed
patients, and elicits a depressed mood in normal sub-
jects, while most antidepressant treatments, including
serotonin-selective reuptake inhibitor (SSRIs), increase
5-HT neurotransmission either directly or indirectly
[20,31-34]. Alterations in 5-HT1A receptor levels are
commonly observed in depressed individuals. In particu-
lar, post-synaptic 5-HT1A receptors are reduced in sev-
eral cortical regions in depression [35-39] and anxiety
[40-45], while 5-HT1A autoreceptors are increased in
depression [46-48]. Elevated 5-HT1A autoreceptor
expression would tend to reduce the activity of 5-HT
neurons, while reduced post-synaptic 5-HT1A receptors
w o u l dr e s u l ti nab l u n t e db e h a v i o r a lr e s p o n s et o5 - H T .
These studies implicate the 5-HT1A receptor as an
important determinant of predisposition to mental ill-
ness. However, the mechanisms underlying these differ-
ential changes in 5-HT1A receptor expression remain
unclear. This review examines the evidence that altera-
tions in transcriptional regulation of the 5-HT1A recep-
tor could underlie its dys-regulation in mental illness.
5-HT1A receptors and the 5-HT system
5-HT1A autoreceptor function
The brain 5-HT system originates from neurons of the
raphe nuclei that express tryptophan hydroxylase 2
(TPH2), the rate-limiting enzyme for 5-HT synthesis in
the central nervous system [49-51] (Figure 1). These
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many functions, including sleep, mood, and stress reac-
tivity [52-58] and are implicated in mental illnesses,
including major depression and anxiety [26,27,55,57,59].
Among the 14 5-HT receptor genes [60], the 5-HT1A
receptor is of particular interest since it is abundant in
corticolimbic regions that are implicated in mood and
emotion, such as the hippocampal and cortical pyrami-
dal neurons and interneurons of the prefrontal cortex,
medial septum, amygdala, hypothalamus, and other
regions [60-64]. Presynaptically, the 5-HT1A receptor is
the major somatodendritic autoreceptor on 5-HT neu-
rons [65-67] where it acts as a “brake” to inhibit the
activity of the entire 5-HT system and is thought to
delay antidepressant response [68-74] (Figure 2). Hence
mechanisms that regulate 5-HT1A autoreceptor levels
are likely to set the tone of the entire 5-HT system and
thus influence susceptibility to mood disorders such as
depression, anxiety, and related disorders.
Signaling of the 5-HT1A autoreceptor
The 5-HT1A receptor was the first 5-HT receptor
cloned and encodes a protein with seven hydrophobic
transmembrane domains, typical of G-protein coupled
receptors [61,75] (Figure 3). The 5-HT1A receptor cou-
ples to Gi/Go proteins, and in most cells and inhibits
adenylyl cyclase activation, reducing cAMP levels
[76,77]. Several studies have investigated the signaling of
the 5-HT1A autoreceptor in raphe neurons [78]. This is
also the case in the raphe nucleus, where the 5-HT1A
autoreceptor preferentially couples to Gai3 [79,80], and
negatively regulates serotonergic neuronal activity, in
part by inhibiting adenylyl cyclase [80-83]. Interestingly,
signaling to this pathway depends on the 5-HT1A ago-
nist used [82,84,85]. In addition, the 5-HT1A autorecep-
tor also activates GIRK potassium channels to inhibit
neuronal firing [86-89], and inhibits voltage-gated cal-
cium channel activity to reduce calcium entry [90-92]
(Figure 3). In post-synaptic cortical neurons, 5-HT1A-
mediated inhibition of cAMP is thought to reduce
CAMKII activity and to reduce AMPA receptor levels
[93]. In hippocampal neurons, 5-HT1A receptor activa-
tion leads to activation of Akt and inactivation of
GSK3b [94-96], which is also seen in raphe cultures
[97], but has no effect on basal ERK1/2 phosphorylation
[95,97]. Using rat raphe RN46A cells, a model of seroto-
nergic neurons that express endogenous 5-HT1A auto-
receptors [98,99], we foundt h a t5 - H T 1 Ar e c e p t o r s
signaled to inhibit of adenylyl cyclase and ERK1/2 phos-
phorylation, and that ERK1/2 inhibition was augmented
upon differentiation of the cells to a serotonergic pheno-
type [100]. Similarly, in cortical neurons and human
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Figure 1 Components of 5-HT neurotransmission. Shown are the major components involved in the synthesis, vesicular packaging, reuptake,
and degradation of serotonin in the brain, and the major receptors that mediate pre- and post-synaptic regulation of 5-HT neurotransmission.
TRP, tryptophan; 5-HTP, 5-hydroxy-TRP; 5-HIAA, 5-hydroxy indole acetic acid; TPH2, tryptophan hydroxylase-2; AADC, aromatic amino-acid
decarboxylase; VMAT2, vesicular monoamine transporter-2; MAO-B, monoamine oxidase B; 5-HTT, 5-HT transporter.
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Page 2 of 14neuronal cultures, the 5-HT1A receptor also inhibits
ERK1/2 activation [101,102]. Thus, modulation of
ERK1/2 activity may be cell- and maturation-dependent
and may also depend on the expression of negative reg-
ulators of this pathway (such as MKP or PP2A)
[103,104]. Therefore, in the raphe, the signaling of the
5-HT1A autoreceptor appears to be largely inhibitory.
5-HT1A receptors and antidepressant response
Although antidepressants such as SSRIs, rapidly block 5-
HT reuptake, chronic 3-wk treatment is required for clin-
ical improvement and desensitization of the 5-HT1A
autoreceptor has been implicated in this delay (Figure 3).
Blier, de Montigny and colleagues demonstrated that
multiple antidepressant treatments reduce auto-inhibi-
tion of serotonergic activity in the raphe nuclei by 5-
HT1A autoreceptors, and in some cases sensitize
responses of post-synaptic 5-HT1A receptors [105]. This
work has led to the concept that chronic desensitization
of the 5-HT1A autoreceptor is necessary to achieve
increased serotonergic neurotransmission following anti-
depressant treatment [106-109] and to increase serotonin
synthesis [110]. Consistent with this, the level of 5-HT1A
autoreceptors is negatively correlated with raphe 5-HT
synthesis in human subjects [74]. The prolonged time
course of 5-HT1A desensitization is consistent with
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Figure 2 5-HT1A autoreceptor-mediated negative feedback on 5-HT neurons. A model of a serotonergic neuron (5-HT neuron) projecting
to a target neuron (postsynaptic neuron) is shown, with 5-HT1A receptors depicted as yellow ovals, and other 5-HT receptors as other colored
ovals. Acutely, SSRI’s rapidly enter the brain and block 5-HT transporters (green diamonds), located at the raphe serotonin nerve terminal, but
also at the cell body and dendrites in the raphe nuclei. This block of reuptake leads to accumulation of extracellular 5-HT (red dots) at both sites
once released by depolarization. Activation of 5-HT1A autoreceptors located at the cell body and dendrites leads to inhibition of neuronal firing
rate (red action potential), thus compensating for increase in 5-HT induced by SSRI treatment, resulting in little change in 5-HT
neurotransmission initially.
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Figure 3 Neuronal signaling of the 5-HT1A autoreceptor. The major signaling pathways of the 5-HT1A receptor in neurons are shown. The
5-HT1A receptor is shown figuratively as a heptahelical G-protein coupled receptor that couples via inhibitory G proteins (Gi/Go) to inhibit
adenylyl cyclase (AC) and reduce cAMP levels; to open G-protein inward rectifying potassium channels (K
+) to reduce membrane potential (Vm);
and to inhibit voltage-gated calcium channels (Ca
++) and reduce intracellular free calcium concentration ([Ca
++]i).
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Page 3 of 14adaptive reduction in 5-HT1A receptor expression, as
opposed to more rapid forms of desensitization such as
receptor uncoupling or internalization. In studies of nor-
mal animals chronically treated with SSRIs, only acute
desensitization of the autoreceptor is observed, with no
changes in 5-HT1A autoreceptor RNA or protein levels
in the raphe [111-113]. In contrast, studies in chronically
stressed or older animals [114] have shown reductions in
5-HT1A RNA in raphe nuclei following chronic antide-
pressant treatment. During chronic SSRI treatment, 5-
HT1A autoreceptors desensitize [107,115-119], leading
to reduced 5-HT1A autoreceptor levels in animal depres-
sion models and depressed subjects [110,120-125], and
restoration of raphe firing activity and 5-HT release.
Thus both acute and chronic desensitization processes
appear to be required for long-term inactivation of 5-
HT1A autoreceptors in SSRI treatment of depressed ani-
mal models. However, the mechanisms involved in the
preferential down-regulation of 5-HT1A autoreceptors,
but not post-synaptic 5-HT1A receptors following
chronic antidepressant treatment remain to be clarified.
Upon treatment with SSRIs, it is presumed that as
well as inhibiting 5-HT reuptake at the nerve terminals
in target brain regions, 5-HT levels are increased at the
cell body and dendrites of raphe neurons leading to
autoinhibition (Figure 2). However, the mechanism by
which SSRI treatment enhances 5-HT release in the
raphe is unclear. Although recurrent collaterals or intra-
raphe cross-innervation occurs in culture [126], it has
been difficult to demonstrate 5-HT terminals in the
raphe nuclei [112]. The finding that VMAT2 is targeted
to dendrites for somatodendritic vesicular dopamine
release [127-129] provides a new mechanism by which
5-HT may be released somatodendritically. Recent evi-
dence suggests that somatodendritic 5-HT release can
occur, at least in culture [130]. But can transcriptional
down-regulation account for a 3-week delay in antide-
pressant response? In cultured cells, siRNA can reduce
target RNA within days, however, the half-life of 5-
HT1A receptor protein in vivo is several days following
doxycycline-induced suppression [131,132]. Further-
more, unlike in culture where signaling to down-regula-
tion is immediate, 5-HT1A-mediated signaling to
transcriptional down-regulation is gradual in vivo since
5-HT release is auto-inhibited and only gradually
increases as autoreceptors become more desensitized, a
process that may take weeks.
5-HT1A receptors in animal models of depression
Due to the limitations of heterogeneity in clinical sam-
ples and in the validity of animal models, our under-
standing of depression remains incomplete [30,133-135].
Nevertheless, mouse models have provided valuable
insights into the role of 5-HT1A receptors in depression
and anxiety. Importantly, 5-HT1A-null mice display
increased anxiety behaviours [136-138] and are unre-
sponsive to selective 5-HT reuptake inhibitor (SSRI) [139].
Conversely, global over-expression of the 5-HT1A recep-
tor or enhancement of its post-synaptic signalling
decreases anxiety [96,140]. Rescue of post-synaptic 5-
HT1A receptor expression in early postnatal forebrain
restores a normal anxiety phenotype, while its inhibition
from postnatal day 13-34 induces anxiety in the adult, sug-
gesting it has a role in development of the anxiety pheno-
type [131,141]. 5-HT1A-dependent inhibition of
CAMKIIa appears to mediate the anxiety phenotype,
since 5-HT1A-null mice with reduced CAMKII activation
did not develop anxiety [141]. Recently, mice with a 30%
decrease in 5-HT1A autoreceptors displayed increase in 5-
HT neuron firing rate and augmented 5-HT release, and
reduced depression-like behavior but no change in anxiety
[132]. Hence, reduced activity of post-synaptic 5-HT1A
receptors is implicated in anxiety, while an increased tran-
scription of 5-HT1A autoreceptors associates with depres-
sion and resistance to chronic SSRI treatment [142].
Transcriptional Regulation of the 5-HT1A
Receptor Gene
Because acute desensitization (uncoupling and internali-
zation) occurs rapidly (sec-min) and is rapidly reversible
[143,144], we postulated that reduced transcription of 5-
HT1A autoreceptors could account for the three-week
delay in clinical response following antidepressant treat-
ment [108,142,145]. Supporting this hypothesis, trans-
g e n i cm i c ew i t ho n l y3 0 %r e p r e s s i o no f5 - H T 1 A
autoreceptors display an enhanced and rapid response
to SSRIs [132], suggesting that transcriptional repression
of the 5-HT1A autoreceptor could be key to an effective
antidepressant response. In characterizing the 5-HT1A
promoter, we have uncovered a number of important
regulators at the minimal promoter, upstream repressor
and enhancer regions, as well as at a C(-1019)G poly-
morphism, that could affect 5-HT1A autoreceptor
expression (Figure 4).
5-HT1A minimal promoter
To examine the transcriptional regulation of the 5-
HT1A receptor gene, the promoter region has been
characterized using transcriptional reporter assays in
cultured cell lines [99,108,146]. Most non-neuronal cell
lines and tissues express low or undetectable levels of 5-
HT1A receptors [61], while some neuronal cell lines
express endogenous 5-HT1A receptors. In particular,
the rat raphe RN46A cells are serotonergic and express
5-HT1A receptors, and can serve as a model for 5-
HT1A autoreceptor regulation [99]. While several non-
serotonergic neuroblastoma cells (human SKN-SH,
rodent NG108-15 and SN-48 cells) also express 5-HT1A
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[147-149]. The human and mouse 5-HT1A promoters
l a c kaT A T Ab o xa n dh a v em u l t i p l et r a n s c r i p t i o ns t a r t
sites, while the rat 5-HT1A promoter has a major
TATA-driven start site [99,146]. Nevertheless, the mini-
mal promoter located within 300 bp upstream of the
intronless coding sequence is highly conserved. This
minimal promoter is typical of a “housekeeping” promo-
ter and consists of a series of GC-rich enhancer ele-
ments recognized by the ubiquitous factors MAZ1 and
Sp1 [146] that drive non-selective expression of the
gene in all cell types, whether they express endogenous
5-HT1A receptors or not [99]. Within the minimal pro-
moter, there is a conserved NFkB response element that
may mediate induction of 5-HT1A expression by NFkB
[150]. NFkB is observed in several types of immune cells
including B- and T-lymphocytes, neutrophils and
macrophages in which basal 5-HT1A receptor levels are
very low, but can be greatly induced by mitogenic sti-
mulation to augment the mitogenic response [151-153].
Finally, there is evidence that suppression of 5-HT1A
receptor expression by glucocorticoids is mediated by
inhibitory actions on the minimal promoter via Sp1 and
NFkB elements [154].
5-HT1A repressor region
Located upstream from the minimal promoter is a series
of repressor elements that silence 5-HT1A expression in
non-neuronal cells, but also repress 5-HT1A transcrip-
tion in neuronal cell lines that express 5-HT1A recep-
tors [155,156]. Importantly these elements are conserved
between human, rat and mouse genes and are func-
tional. One of the key elements is a consensus repressor
element-1 (RE-1) site that is recognized by REST/NRSF,
a key pan-neuronal repressor of multiple neuronal genes
[157-159]. REST has been shown to be crucial for silen-
cing neuronal gene expression in neural stem cells or
progenitors and non-neuronal cells, but is down-regu-
lated upon neuronal differentiation, allowing for expres-
sion of neuronal genes. However, the 5-HT1A receptor
is not expressed in all neuronal subtypes, hence addi-
tional repressors are required to restrict its expression
to appropriate neurons. Located adjacent to the RE-1
site, we identified a dual repressor element (DRE, 31-bp)
that mediates the strongest repression of the 5-HT1A
promoter (Figure 4) [156]. In non-neuronal cells two
nuclear protein complexes bind the DRE, one at the 5’
end (FRE), and the other at the 3’ end (TRE); however
in raphe RN46A cells only the FRE-complex is present.
In raphe RN46A cells, mutation of the FRE de-repressed
5-HT1A transcription by 10-fold, whereas in non-neuro-
nal cells, deletion of the entire DRE was required. Using
a yeast one-hybrid cloning approach Freud-1/CC2D1A
(FRE Under Dual repression binding protein) was iden-
tified as a protein that binds and represses at the FRE
site [160]; subsequently, the homologue Freud-2/
+  + 
Freud-1 REST  Deaf1 
Hes1/ 
Hes5  GR/MR NFκB  MAZ Sp1 
DRE DRE RE-1  C/G  nGRE NRE 
GR/MR 
-1019 
Freud-2 
+ 
Pet1 
Figure 4 Identified promoter elements of the human 5-HT1A receptor gene (HTR1A). The location of identified DNA elements on the 5-
HT1A 5’ regions flanking the start of translation (bold arrow) are shown figuratively. Identified activators (arrows) or repressors (bars) of
transcription are also shown. Within the minimal promoter (box) there are GC-rich Sp1 and MAZ elements (+); NFkB response element (NRE);
and glucocorticoid receptors (GR/MR) that inhibit transcription by blocking Sp1. Further upstream in a repressor/enhancer regions, a negative
glucocorticoid response element (nGRE) also mediates direct GR/MR-induced repression. Hes and Deaf1 proteins repress the 5-HT1A promoter at
the C(-1019) allele, while in serotonin neurons Pet-1 exerts strong enhancer activity. A strong repressor region that silences expression in 5-HT1A-
negative non-neuronal cells, but also represses in 5-HT1A-positive neuronal cells is located upstream that includes elements for REST (RE-1),
Freud-1 and Freud-2 (DRE).
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Page 5 of 14CC2D1B was identified as the second DRE-binding pro-
tein [161,162]. Freud-1 and Freud-2 are colocalized with
5-HT1A receptors in neurons, where they play comple-
mentary roles to regulate the level of 5-HT1A receptor
expression. In particular, Freud-1, but not Freud-2, is
strongly expressed and colocalized with 5-HT and 5-
HT1A receptors in raphe nuclei, while both Freud-1
and Freud-2 are colocalized with the receptor in post-
synaptic areas such as cortex and hippocampus
[161,163]. Together, Freud-1 and Freud-2 mediate dual
repression of 5-HT1A receptor expression in most cell
types including many post-synaptic neurons to restrict
5-HT1A receptor expression to appropriate neurons.
Based on its role in RN46A cells and its localization in
5-HT neurons in vivo, Freud-1 appears to be the domi-
nant repressor of 5-HT1A autoreceptor expression.
However, it is possible that in mental illness, other
repressors may play a role. For example, REST expres-
sion is up-regulated in serotonergic raphe cells from
depressed suicide as compared to control brains, and
may restrain over-expression of 5-HT1A autoreceptors
observed in these subjects [164].
Located between the minimal promoter and the
upstream DRE is a region that exhibits both enhancer
and repressor activities (Figure 4). Within this region, a
novel type of negative glucocorticoid response element
(nGRE), composed of two GRE half-sites separated by 6
nucleotides (rather than 3 nucleotides as for a typical
consensus GRE) [165] was identified. The nGRE is con-
served between human, mouse and rat, although its
function has only been demonstrated for the rat nGRE
thus far. The 5-HT1A nGRE mediates synergistic
repression by both high and low affinity glucocorticoid
receptors (MR and GR), suggesting a key role in repres-
sion of 5-HT1A receptors in the hippocampus, in which
both these receptors are present [166]. In the raphe,
only GR has been detected, and it appears to have a
relatively weaker ability to suppress 5-HT1A receptor
expression compared to hippocampus [167-171]. Inter-
estingly, 5-HT1A agonists downregulate GR in raphe
cells in culture, which would lead to an increase in 5-
HT1A autoreceptors [172]. Conversely, knockdown of
GR abrogates the down-regulation of 5-HT1A autore-
ceptors induced by chronic mild stress in mice [173].
Since glucocorticoids are dys-regulated in depression,
the chronic elevation of cortisol may ultimately desensi-
tize GR and could contribute to increase 5-HT1A auto-
receptor expression in depression.
C(-1019)G HTR1A polymorphism (rs6295)
In our analysis of the 5-HT1A promoter we identified a
human C(-1019)G 5-HT1A polymorphism located
within the repressor/enhancer region. The G allele and
G/G genotype were associated with major depression
and suicide [174,175]. Since the C(-1019)G polymorph-
ism is located in a 26-bp palindrome, we addressed
whether this palindrome could bind protein in nuclear
extracts of raphe RN46A cel l s ,a n ds h o w e das p e c i f i c
complex that preferentially recognized the C-allele over
the G-allele. Using a yeast one-hybrid screen, Deaf1
(NUDR) and Hes5 were identified as repressors of the
C- but not the G-allele of the 5-HT1A promoter (Figure
4). Deaf1 (Deformed autoregulatory factor-1) binds to a
minimal TCG consensus sequence [176] present in the
human, rat and mouse 5-HT1A genes [175] and can act
as a repressor or enhancer [176,177]. By supershift ana-
lysis, Deaf1 was detected as a major component of the
RN46A nuclear protein C-allele palindrome-binding
complex. When transfected in RN46A cells, Deaf1 sup-
pressed 5-HT1A receptor transcription, and reduced 5-
HT1A RNA and protein expression. However, unlike
Freud-1, while mutation of the palindrome blocked
Deaf1 repression, it did not de-repress basal 5-HT1A
transcription compared to mutation of the FRE, suggest-
ing that Freud-1 is the predominant repressor of the
autoreceptor in RN46A cells. In the adult rat and
human brain, Deaf1 is colocalized with 5-HT1A recep-
tors, and in the raphe nuclei it is also colocalized with
5-HT [175,178]. In other neuronal 5-HT1A-expressing
cell types, instead of repressing 5-HT1A gene expression
as seen in raphe or non-neuronal cells, Deaf1 enhances
5-HT1A expression, and the G-allele reduces basal 5-
HT1A expression [148]. Based on this dual activity of
Deaf1, the G/G(-1019) genotype is expected to increase
5-HT1A autoreceptor levels to reduce 5-HT neuron fir-
ing, and decrease post-synaptic 5-HT1A receptors,
thereby synergistically reducing 5-HT neurotransmission
(Figure 5). In support of this, depressed subjects homo-
zygous for the 5-HT1A G/G(-1019) genotype have
increased 5-HT1A autoreceptor binding potential
[179-181], which is consistent with the increase in 5-
HT1A autoreceptors observed in post-mortem studies
of depressed suicides [46-48]. Thus, the 5-HT1A G
(-1019) allele may alter 5-HT1A receptor expression in
vivo by blocking Deaf1 function.
The Hes proteins, which also preferentially recognize
the HTR1A C(-1019) allele, appear to play an important
role in regulating early induction of the 5-HT1A autore-
ceptor. Hes5, and especially Hes1, repress neuronal gene
expression in neural precursor cells and are down-regu-
lated upon neuronal differentiation [182]. We therefore
addressed whether Hes1 can repress 5-HT1A receptor
expression, and found that Hes1 exerts even stronger
repression than either Hes5 or Deaf1. However, Deaf1
appears to be the dominant factor when the two are co-
expressed [183]. To address whether Hes1 influences 5-
HT1A receptor expression in vivo,w ee x a m i n e d
embryonic midbrain tissue from the Hes1 -/- mice for
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Page 6 of 145-HT1A receptor RNA levels at the initiation of seroto-
nergic neuronal differentiation. We found that 5-HT1A
RNA was prematurely upregulated with an expanded dis-
tribution of midbrain expression. Thus, reduction in
repression by both Deaf1 and Hes proteins at the G-allele
of the 5-HT1A promoter could lead to upregulation of 5-
HT1A autoreceptor expression beginning in early seroto-
nergic differentiation and extending to adulthood.
The expression of Deaf1, Freud-1 and Freud-2 also
appears to be dys-regulated in human depression in a
region-specific manner [161,164,178,184]. In serotoner-
gic raphe cells, both Deaf1 and REST are upregulated,
and 5-HT1D receptor RNA is increased, and there is a
trend for increased 5-HT1A and 5-HT1B RNA [164].
Hence, despite compensatory upregulation of repressors,
there appears to be a general upregulation of 5-HT1
autoreceptor expression on serotonergic neurons. How-
ever, the G-allele would be expected to attenuate Deaf1
action on the 5-HT1A receptor gene.
Pet-1 enhancer elements
In addition to repression, 5-HT1A autoreceptor expres-
sion is subject to regulation by enhancers, the most
important of which appears to be Pet-1. Pet-1 was
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Figure 5 Proposed actions of 5-HT1A C(-1019)G genotype in normal vs. depressed subjects. In normal subjects containing homozygous
HTR1A C/C (-1019) genotype, 5-HT neurons fire at their normal rate (red action potentials), releasing 5-HT (red dots) at the synapse for activation
of receptors (ovals), and to a lesser degree at the raphe cell body to restrain neuronal activity by negative feedback through the 5-HT1A
autoreceptor (yellow ovals). In the G/G genotype and in depressed subjects, 5-HT1A autoreceptor expression is increased which would reduce
neuronal firing and 5-HT release, while post-synaptic 5-HT1A receptors are reduced in certain regions, which would decrease response to 5-HT
release. Normal subjects with the G/G genotype have a lesser increase of 5-HT1A autoreceptors, and are able to compensate for the effect of
the G/G genotype on transcription.
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Page 7 of 14identified as a critical regulator of 5-HT marker genes
including TPH, 5-HTT, and ADC genes [185], and
knockout of Pet-1 results in a substantial loss of seroto-
nin in the brain, although a few 5-HT neurons appear
to persist [186]. Hence we addressed whether Pet-1 reg-
ulates 5-HT1A receptor gene transcription [187]. There
are several putative Pet-1 sites located in the 5-HT1A
promoter, and deletion analysis demonstrated that while
all of the sites have some activity, deletion of the
upstream Pet-1 site located at -1406 bp reduced 5-
HT1A promoter activity by over 90%, indicating a pre-
dominant role for this site. Consistent with a role for
Pet-1 in regulation of 5-HT1A autoreceptor expression
in vivo, the Pet-1 knockout mice demonstrated a nearly
complete loss of 5-HT1A RNA and protein specifically
in the raphe [187-189], while at post-synaptic target tis-
sues 5-HT1A expression was modestly affected [187].
Thus, Pet-1 functions as a major enhancer of 5-HT1A
autoreceptor expression. However, since Pet-1 is also
required for TPH2 expression, blocking Pet-1 would
actually reduce 5-HT neurotransmission as shown in
the Pet-1 knockout mice, which leads to an anxious and
aggressive behavioral phenotype [186].
In summary, we have identified several key transcrip-
tion factors, including REST, Freud-1, GR, Deaf1, Hes1
and Pet-1, which coordinately regulate 5-HT1A autore-
ceptor expression and its modulation by glucocorticoids,
5-HT, and other neurotransmitters.
5-HT1A Autoreceptors in Human Depression
Given the role of 5-HT1A autoreceptors in regulation of
the serotonin system and the importance of 5-HT in
clinical depression, several approaches have addressed
whether 5-HT1A receptor expression is altered in
depression. In depressed subjects, the observed increases
in 5-HT1A autoreceptors could be due to increased 5-
HT1A autoreceptor transcription, while region-specific
reductions in post-synaptic 5-HT1A receptors could
result from reduced transcription in these regions.
These changes in 5-HT1A receptors would result in a
global reduction in 5-HT neurotransmission, and predis-
position to depression (Figure 5). In agreement with this
idea, the G(-1019) 5-HT1A allele, which leads to
increased 5-HT1A autoreceptor transcription, has been
associated with major depression and suicide [175], and
this association has been replicated and extended in
most [174,179,181,190-197], but not all studies [198].
The 5-HT1A G(-1019) allele has also been associated
with anxiety [199-202]. Importantly, the 5-HT1A G/G
genotype is associated with increased 5-HT1A autore-
ceptors in depressed subjects [179-181], suggesting that
5-HT1A G(-1019) allele is a risk factor for depression
by increasing 5-HT1A autoreceptor levels to reduce
5-HT neurotransmission [108,145]. Interestingly, studies
in normal subjects have not found an association of the
G/G genotype with depressed or anxious mood [203].
Furthermore, in normal subjects, although a trend for
increased 5-HT1A autoreceptor levels with the G/G
genotype is observed, it was not statistically significant
[204]. These results suggest that although the G-allele
may promote higher expression of 5-HT1A autorecep-
tors (Figure 5), normal subjects are able to compensate
for the effect of the G allele,w h i l ed e p r e s s e dp a t i e n t s
are not. For example, the absolute level of 5-HT1A
receptors may differ between depressed and normal sub-
jects due to differences in the regulation of 5-HT1A
expression (e.g., by increased glucocorticoids) or in the
expression of 5-HTT, TPH2, MAO or other genes that
influence the amount of 5-HT that is present extracellu-
larly in the raphe [205,206] and would indirectly affect
the level of 5-HT1A autoreceptors through regulating
autoreceptor desensitization. In addition, it is possible
that impairment of Deaf1 action could account for
increased levels of 5-HT1A autoreceptors in G/G sub-
jects, and could also mediate a reduction in post-synap-
tic 5-HT1A receptors, suggesting Deaf1 as a potentially
important mediator of transcriptional dys-regulation of
the 5-HT1A receptor gene in depression.
An increase in 5-HT1A autoreceptor levels delays or
prevents antidepressant response [132] and 3 weeks of
treatment with antidepressants is required for clinical
improvement, due to recurrent inhibition of raphe activ-
ity by the 5-HT1A autoreceptor (Figure 2). One strategy
to overcome negative feedback by 5-HT1A autoreceptor
has been to use 5-HT1A partial agonists such as pindo-
lol or buspirone, to block or desensitize the autorecep-
tor and accelerate SSRI action [207-209]. However,
these compounds have insufficient specificity since they
affect both pre-and post-synaptic receptors, and display
only partial specificity for 5-HT1A autoreceptors
[210,211]. We and others have found that the G(-1019)
allele associates with reduced antidepressant response
[174,212-214], suggesting that regulation by Deaf1 could
facilitate antidepressant response. Successful treatment
of panic disorder patients with chronic SSRIs correlates
with a normalization of pre- and post-synaptic 5-HT1A
receptors, suggesting that down-regulation of pre-synap-
tic receptors concomitant with an up-regulation of post-
synaptic 5-HT1A receptors may be critical for treatment
response [45,215]. Among the transcriptional regulators
of the 5-HT1A promoter, Deaf1 is of particular interest
since it displays repressor activity on 5-HT1A autore-
ceptor expression, but enhancer activity on post-synap-
tic 5-HT1A receptors, a combination of activities that
would normalize pre- and post-synaptic 5-HT1A recep-
tor levels to enhance serotonergic neurotransmission.
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In conclusion, since dys-regulation of the 5-HT1A auto-
receptor has the potential to affect the activity of the
entire 5-HT system, it is critical to identify the tran-
scriptional mechanisms underlying its long-term regula-
tion. Understanding the transcription factors involved
may provide important clues to the molecular mechan-
isms responsible for 5-HT1A receptor dys-regulation in
mental illness. Transcriptional regulators of the 5-HT1A
autoreceptor may also constitute important targets to
restore normal levels of the receptor and improve treat-
ment outcome for depression and related mental
illnesses.
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